Literature DB >> 19744318

Commentary: the role of cytologic analysis of voided urine in the work-up of asymptomatic microhematuria.

Deep Trivedi1, Edward M Messing.   

Abstract

Microscopic hematuria is a common finding in patients presenting to both primary care doctors as well as urologists. Sources of microscopic hematuria include infection, stones, inflammatory disorders as well as cancer of the genitourinary tract, particularly urothelial cancer. A primary focus in the urologic workup of hematuria is to rule out cancer. This is done using radiographic studies as well as procedures such as cystoscopy and bladder biopsy. As the authors state in their article titled "The utility of serial urinary cytology in the initial evaluation of the patient with microscopic hematuria", cytologic analysis of voided urine, though attractive due to its noninvasive nature, has been found to have the neither the sensitivity, cost-effectiveness, nor the ease of administration necessary to replace more invasive diagnostics in the evaluation of microscopic hematuria.

Entities:  

Mesh:

Year:  2009        PMID: 19744318      PMCID: PMC2753578          DOI: 10.1186/1471-2490-9-13

Source DB:  PubMed          Journal:  BMC Urol        ISSN: 1471-2490            Impact factor:   2.264


  12 in total

1.  Evaluation of asymptomatic microscopic hematuria in adults: the American Urological Association best practice policy--part II: patient evaluation, cytology, voided markers, imaging, cystoscopy, nephrology evaluation, and follow-up.

Authors:  G D Grossfeld; M S Litwin; J S Wolf; H Hricak; C L Shuler; D C Agerter; P R Carroll
Journal:  Urology       Date:  2001-04       Impact factor: 2.649

Review 2.  Urine cytology. It is still the gold standard for screening?

Authors:  F M Brown
Journal:  Urol Clin North Am       Date:  2000-02       Impact factor: 2.241

Review 3.  Carcinoma in situ of the urinary bladder: review of clinicopathologic characteristics with an emphasis on aspects related to molecular diagnostic techniques and prognosis.

Authors:  Nalan Nese; Ruta Gupta; Matthew H T Bui; Mahul B Amin
Journal:  J Natl Compr Canc Netw       Date:  2009-01       Impact factor: 11.908

4.  Comparison of bladder cancer outcome in men undergoing hematuria home screening versus those with standard clinical presentations.

Authors:  E M Messing; T B Young; V B Hunt; K W Gilchrist; M A Newton; L L Bram; W J Hisgen; E B Greenberg; M E Kuglitsch; J D Wegenke
Journal:  Urology       Date:  1995-03       Impact factor: 2.649

5.  Is cytology required for a hematuria evaluation?

Authors:  Chris A Hofland; Albert J Mariani
Journal:  J Urol       Date:  2004-01       Impact factor: 7.450

6.  The sensitivity of bladder wash flow cytometry, bladder wash cytology, and voided cytology in the detection of bladder carcinoma.

Authors:  R A Badalament; D K Hermansen; M Kimmel; H Gay; H W Herr; W R Fair; W F Whitmore; M R Melamed
Journal:  Cancer       Date:  1987-10-01       Impact factor: 6.860

7.  Differences between local and review urinary cytology in diagnosis of bladder cancer. An interobserver multicenter analysis.

Authors:  Mika-P Raitanen; Risto Aine; Erkki Rintala; Jukka Kallio; Pertti Rajala; Harri Juusela; Teuvo L J Tammela
Journal:  Eur Urol       Date:  2002-03       Impact factor: 20.096

8.  Comparison of NMP22 BladderChek test and urine cytology for the detection of recurrent bladder cancer.

Authors:  Atul Kumar; Rajeev Kumar; Narmada P Gupta
Journal:  Jpn J Clin Oncol       Date:  2006-03-06       Impact factor: 3.019

Review 9.  Long-term outcome of home dipstick testing for hematuria.

Authors:  Ralph Madeb; Edward M Messing
Journal:  World J Urol       Date:  2007-11-27       Impact factor: 4.226

10.  Utility of serial urinary cytology in the initial evaluation of the patient with microscopic hematuria.

Authors:  Kogenta Nakamura; Ali Kasraeian; Kenneth A Iczkowski; Myron Chang; John Pendleton; Satoshi Anai; Charles J Rosser
Journal:  BMC Urol       Date:  2009-09-10       Impact factor: 2.264

View more
  6 in total

Review 1.  Molecular diagnostic trends in urological cancer: biomarkers for non-invasive diagnosis.

Authors:  V Urquidi; C J Rosser; S Goodison
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

2.  Urinary glycoprotein biomarker discovery for bladder cancer detection using LC/MS-MS and label-free quantification.

Authors:  Na Yang; Shun Feng; Kerby Shedden; Xiaolei Xie; Yashu Liu; Charles J Rosser; David M Lubman; Steven Goodison
Journal:  Clin Cancer Res       Date:  2011-04-01       Impact factor: 12.531

3.  A candidate molecular biomarker panel for the detection of bladder cancer.

Authors:  Virginia Urquidi; Steve Goodison; Yunpeng Cai; Yijun Sun; Charles J Rosser
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-10-24       Impact factor: 4.254

Review 4.  The health economics of bladder cancer: an updated review of the published literature.

Authors:  Christina Yeung; Tuan Dinh; Joseph Lee
Journal:  Pharmacoeconomics       Date:  2014-11       Impact factor: 4.981

5.  MULTIPLEX URINARY TESTS FOR BLADDER CANCER DIAGNOSIS.

Authors:  Virginia Urquidi; Charles J Rosser; Steve Goodison
Journal:  Eur Med J Urol       Date:  2013

Review 6.  Bladder cancer detection and monitoring: assessment of urine- and blood-based marker tests.

Authors:  Steve Goodison; Charles J Rosser; Virginia Urquidi
Journal:  Mol Diagn Ther       Date:  2013-04       Impact factor: 4.074

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.